Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety & Efficacy of Perampanel in Indian Patients as An Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Patients With Epilepsy Aged 12 Years or Older

Next Previous
Trial Profile

A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety & Efficacy of Perampanel in Indian Patients as An Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Patients With Epilepsy Aged 12 Years or Older

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Myoclonic epilepsies; Partial epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Adverse reactions
  • Sponsors Eisai Inc

Most Recent Events

  • 01 Sep 2021 Results post hoc analysis evaluated the tolerability of post hoc analysis efficacy evaluating tolerability and efficacy of adjunctive perampanel in patients aged 12-18 years with FOS, presented at the 34th International Epilepsy Congress
  • 01 Sep 2021 Results presented at the 34th International Epilepsy Congress
  • 01 Sep 2021 Results of post-hoc analysis assessing real-world tolerability and efficacy of adjunctive perampanel in Indian patients aged equal to or greater 12 years ; stratified by seizure type presented at the 34th International Epilepsy Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top